Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J.

EMBO Mol Med. 2018 Apr 12. pii: e8446. doi: 10.15252/emmm.201708446. [Epub ahead of print]

2.

Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.

Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, Hashimoto A, Vonteddu P, Behera R, Goins MA, Mulligan C, Nam B, Hockstein N, Denstman F, Shakamuri S, Speicher DW, Weeraratna AT, Chao T, Vonderheide RH, Languino LR, Ordentlich P, Liu Q, Xu X, Lo A, Puré E, Zhang C, Loboda A, Sepulveda MA, Snyder LA, Gabrilovich DI.

Cancer Cell. 2017 Nov 13;32(5):654-668.e5. doi: 10.1016/j.ccell.2017.10.005.

PMID:
29136508
3.

Syntaphilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer.

Caino MC, Seo JH, Wang Y, Rivadeneira DB, Gabrilovich DI, Kim ET, Weeraratna AT, Languino LR, Altieri DC.

J Clin Invest. 2017 Oct 2;127(10):3755-3769. doi: 10.1172/JCI93172. Epub 2017 Sep 11.

4.

ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma.

Ndoye A, Budina-Kolomets A, Kugel CH 3rd, Webster MR, Kaur A, Behera R, Rebecca VW, Li L, Brafford PA, Liu Q, Gopal YNV, Davies MA, Mills GB, Xu X, Wu H, Herlyn M, Nicastri MC, Winkler JD, Soengas MS, Amaravadi RK, Murphy ME, Weeraratna AT.

Cancer Res. 2017 Nov 1;77(21):5873-5885. doi: 10.1158/0008-5472.CAN-17-0907. Epub 2017 Sep 8.

PMID:
28887323
5.

When metastasis 'Spns' out of control: Coverage of 'Genome-wide in vivo screen identifies novel host regulators of metastatic colonization'.

Webster MR, Kugel CH 3rd, Weeraratna AT.

Pigment Cell Melanoma Res. 2017 Jul;30(4):384-385. doi: 10.1111/pcmr.12588. Epub 2017 Jun 13. No abstract available.

PMID:
28299902
6.

Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho.

Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH 3rd, Alicea GM, Wang J, Ghosh K, Cheng P, Lisanti S, Marchbank K, Dang V, Levesque M, Dummer R, Xu X, Herlyn M, Aplin AE, Roesch A, Caino C, Altieri DC, Weeraratna AT.

Clin Cancer Res. 2017 Jun 15;23(12):3181-3190. doi: 10.1158/1078-0432.CCR-17-0201. Epub 2017 Feb 23.

PMID:
28232477
7.

Modeling the two-way feedback between contractility and matrix realignment reveals a nonlinear mode of cancer cell invasion.

Ahmadzadeh H, Webster MR, Behera R, Jimenez Valencia AM, Wirtz D, Weeraratna AT, Shenoy VB.

Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):E1617-E1626. doi: 10.1073/pnas.1617037114. Epub 2017 Feb 14.

8.

UNRelenting Translation UNRestrains Melanoma Migration.

Weeraratna AT, Gorospe M.

Cancer Cell. 2016 Nov 14;30(5):655-657. doi: 10.1016/j.ccell.2016.10.012.

9.

In the Wnt-er of life: Wnt signalling in melanoma and ageing.

Kaur A, Webster MR, Weeraratna AT.

Br J Cancer. 2016 Nov 22;115(11):1273-1279. doi: 10.1038/bjc.2016.332. Epub 2016 Oct 20. Review.

10.

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.

Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Ribas A.

Cancer Immunol Res. 2016 Oct;4(10):845-857. Epub 2016 Sep 2.

11.

Autophagy- An emerging target for melanoma therapy.

Ndoye A, Weeraratna AT.

F1000Res. 2016 Jul 29;5. pii: F1000 Faculty Rev-1888. doi: 10.12688/f1000research.8347.1. eCollection 2016. Review.

12.

Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT.

Nature. 2016 Sep 8;537(7619):254. doi: 10.1038/nature18939. Epub 2016 Jul 6. No abstract available.

PMID:
27383789
13.

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH 3rd, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT.

Nature. 2016 Apr 14;532(7598):250-4. doi: 10.1038/nature17392. Epub 2016 Apr 4.

14.

HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors.

Budina-Kolomets A, Webster MR, Leu JI, Jennis M, Krepler C, Guerrini A, Kossenkov AV, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Wu H, Yin X, Liu Q, Lu Y, Mills GB, Xu X, George DL, Weeraratna AT, Murphy ME.

Cancer Res. 2016 May 1;76(9):2720-30. doi: 10.1158/0008-5472.CAN-15-2137. Epub 2016 Mar 16.

15.

Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.

Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G, Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, Herlyn M, Vultur A.

Pigment Cell Melanoma Res. 2016 May;29(3):317-28. doi: 10.1111/pcmr.12465. Epub 2016 Mar 21.

16.

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.

Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M.

Clin Cancer Res. 2016 Apr 1;22(7):1592-602. doi: 10.1158/1078-0432.CCR-15-1762. Epub 2015 Dec 16.

17.

The Wnts of change: How Wnts regulate phenotype switching in melanoma.

Webster MR, Kugel CH 3rd, Weeraratna AT.

Biochim Biophys Acta. 2015 Dec;1856(2):244-51. doi: 10.1016/j.bbcan.2015.10.002. Epub 2015 Nov 4. Review.

18.

Genetically-defined ovarian cancer mouse models.

Morin PJ, Weeraratna AT.

J Pathol. 2016 Jan;238(2):180-4. doi: 10.1002/path.4663. Review.

PMID:
26496815
19.

PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.

Caino MC, Ghosh JC, Chae YC, Vaira V, Rivadeneira DB, Faversani A, Rampini P, Kossenkov AV, Aird KM, Zhang R, Webster MR, Weeraratna AT, Bosari S, Languino LR, Altieri DC.

Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8638-43. doi: 10.1073/pnas.1500722112. Epub 2015 Jun 29.

20.

Novel Protein Kinase C-Mediated Control of Orai1 Function in Invasive Melanoma.

Hooper R, Zhang X, Webster M, Go C, Kedra J, Marchbank K, Gill DL, Weeraratna AT, Trebak M, Soboloff J.

Mol Cell Biol. 2015 Aug;35(16):2790-8.

21.

UV-Induced Wnt7a in the Human Skin Microenvironment Specifies the Fate of Neural Crest-Like Cells via Suppression of Notch.

Fukunaga-Kalabis M, Hristova DM, Wang JX, Li L, Heppt MV, Wei Z, Gyurdieva A, Webster MR, Oka M, Weeraratna AT, Herlyn M.

J Invest Dermatol. 2015 Jun;135(6):1521-1532. doi: 10.1038/jid.2015.59. Epub 2015 Feb 23.

22.

Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells.

Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W 3rd, Becker KG, Kossenkov AV, Frederick DT, Flaherty KT, Xu X, Herlyn M, Murphy ME, Weeraratna AT.

Pigment Cell Melanoma Res. 2015 Mar;28(2):184-95. doi: 10.1111/pcmr.12330. Epub 2014 Dec 29.

23.

Meeting report from the 10th International Congress of the Society for Melanoma Research, Philadelphia, PA, November 2013.

Vultur A, O'Connell M, Webster M, Villanueva J, Herlyn D, Somasundaram R, Krepler C, Zaidi R, Patton E, Sekulic A, Jonsson G, Weeraratna AT.

Pigment Cell Melanoma Res. 2014 Jul;27(4):E1-E12. doi: 10.1111/pcmr.12240. Epub 2014 May 6. No abstract available.

24.

Bisphosphonamidate clodronate prodrug exhibits selective cytotoxic activity against melanoma cell lines.

Webster MR, Kamat C, Connis N, Zhao M, Weeraratna AT, Rudek MA, Hann CL, Freel Meyers CL.

Mol Cancer Ther. 2014 Feb;13(2):297-306. doi: 10.1158/1535-7163.MCT-13-0315. Epub 2013 Dec 5.

25.

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, Indig FE, Flaherty KT, Wargo JA, Frederick DT, Cooper ZA, Nair S, Amaravadi RK, Schuchter LM, Karakousis GC, Xu W, Xu X, Weeraratna AT.

Cancer Discov. 2013 Dec;3(12):1378-93. doi: 10.1158/2159-8290.CD-13-0005. Epub 2013 Oct 8.

26.

Change is in the air: the hypoxic induction of phenotype switching in melanoma.

O'Connell MP, Weeraratna AT.

J Invest Dermatol. 2013 Oct;133(10):2316-2317. doi: 10.1038/jid.2013.208.

27.

A Wnt-er migration: the confusing role of β-catenin in melanoma metastasis.

Webster MR, Weeraratna AT.

Sci Signal. 2013 Mar 26;6(268):pe11. doi: 10.1126/scisignal.2004114. Review.

PMID:
23532332
28.

Cyclophilin D extramitochondrial signaling controls cell cycle progression and chemokine-directed cell motility.

Tavecchio M, Lisanti S, Lam A, Ghosh JC, Martin NM, O'Connell M, Weeraratna AT, Kossenkov AV, Showe LC, Altieri DC.

J Biol Chem. 2013 Feb 22;288(8):5553-61. doi: 10.1074/jbc.M112.433045. Epub 2013 Jan 9.

29.

Molecular signature and in vivo behavior of bone marrow endosteal and subendosteal stromal cell populations and their relevance to hematopoiesis.

Balduino A, Mello-Coelho V, Wang Z, Taichman RS, Krebsbach PH, Weeraratna AT, Becker KG, de Mello W, Taub DD, Borojevic R.

Exp Cell Res. 2012 Nov 15;318(19):2427-37. doi: 10.1016/j.yexcr.2012.07.009. Epub 2012 Jul 27.

30.

Automatic detection of melanoma progression by histological analysis of secondary sites.

Orlov NV, Weeraratna AT, Hewitt SM, Coletta CE, Delaney JD, Mark Eckley D, Shamir L, Goldberg IG.

Cytometry A. 2012 May;81(5):364-73. doi: 10.1002/cyto.a.22044. Epub 2012 Mar 29.

31.

RAF around the edges--the paradox of BRAF inhibitors.

Weeraratna AT.

N Engl J Med. 2012 Jan 19;366(3):271-3. doi: 10.1056/NEJMe1111636. No abstract available.

PMID:
22256810
32.

A spoonful of sugar makes the melanoma go: the role of heparan sulfate proteoglycans in melanoma metastasis.

O'Connell MP, Weeraratna AT.

Pigment Cell Melanoma Res. 2011 Dec;24(6):1133-47. doi: 10.1111/j.1755-148X.2011.00918.x. Epub 2011 Nov 2. Review.

PMID:
21978367
33.

Loss of Klotho during melanoma progression leads to increased filamin cleavage, increased Wnt5A expression, and enhanced melanoma cell motility.

Camilli TC, Xu M, O'Connell MP, Chien B, Frank BP, Subaran S, Indig FE, Morin PJ, Hewitt SM, Weeraratna AT.

Pigment Cell Melanoma Res. 2011 Feb;24(1):175-86. doi: 10.1111/j.1755-148X.2010.00792.x. Epub 2010 Dec 1.

34.

The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report.

Eichhoff OM, Zipser MC, Xu M, Weeraratna AT, Mihic D, Dummer R, Hoek KS.

Melanoma Res. 2010 Aug;20(4):349-55. doi: 10.1097/CMR.0b013e32833bd89e.

35.

Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progression.

Camilli TC, Weeraratna AT.

Biochem Pharmacol. 2010 Sep 1;80(5):702-11. doi: 10.1016/j.bcp.2010.03.002. Epub 2010 Mar 6. Review.

36.

Lack of Wnt5A expression in Merkel cell carcinoma.

Weeraratna AT, Houben R, O'Connell MP, Becker JC.

Arch Dermatol. 2010 Jan;146(1):88-9. doi: 10.1001/archdermatol.2009.348. No abstract available.

37.

The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma.

O'Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, French AD, Dissanayake SK, Indig FE, Bernier M, Taub DD, Hewitt SM, Weeraratna AT.

Oncogene. 2010 Jan 7;29(1):34-44. doi: 10.1038/onc.2009.305. Epub 2009 Oct 5.

38.

Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt.

O'Connell MP, Weeraratna AT.

Pigment Cell Melanoma Res. 2009 Dec;22(6):724-39. doi: 10.1111/j.1755-148X.2009.00627.x. Epub 2009 Aug 25. Review.

39.

Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells.

O'Connell MP, Fiori JL, Kershner EK, Frank BP, Indig FE, Taub DD, Hoek KS, Weeraratna AT.

J Biol Chem. 2009 Oct 16;284(42):28704-12. doi: 10.1074/jbc.M109.028498. Epub 2009 Aug 20.

40.

NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation.

Buac K, Xu M, Cronin J, Weeraratna AT, Hewitt SM, Pavan WJ.

Pigment Cell Melanoma Res. 2009 Dec;22(6):773-84. doi: 10.1111/j.1755-148X.2009.00616.x. Epub 2009 Jul 30.

41.

Active Notch1 confers a transformed phenotype to primary human melanocytes.

Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, Brafford PA, Xiao M, Himes B, Zabierowski SE, Yashiro-Ohtani Y, Nathanson KL, Bengston A, Pollock PM, Weeraratna AT, Nickoloff BJ, Pear WS, Capobianco AJ, Herlyn M.

Cancer Res. 2009 Jul 1;69(13):5312-20. doi: 10.1158/0008-5472.CAN-08-3767. Epub 2009 Jun 23.

42.

Activation of Wnt5A signaling is required for CXC chemokine ligand 12-mediated T-cell migration.

Ghosh MC, Collins GD, Vandanmagsar B, Patel K, Brill M, Carter A, Lustig A, Becker KG, Wood WW 3rd, Emeche CD, French AD, O'Connell MP, Xu M, Weeraratna AT, Taub DD.

Blood. 2009 Aug 13;114(7):1366-73. doi: 10.1182/blood-2008-08-175869. Epub 2009 Jun 11.

43.

Phenylmethimazole decreases Toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration.

Schwartz AL, Malgor R, Dickerson E, Weeraratna AT, Slominski A, Wortsman J, Harii N, Kohn AD, Moon RT, Schwartz FL, Goetz DJ, Kohn LD, McCall KD.

Clin Cancer Res. 2009 Jun 15;15(12):4114-22. doi: 10.1158/1078-0432.CCR-09-0005. Epub 2009 May 26.

44.

Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma.

Palavalli LH, Prickett TD, Wunderlich JR, Wei X, Burrell AS, Porter-Gill P, Davis S, Wang C, Cronin JC, Agrawal NS, Lin JC, Westbroek W, Hoogstraten-Miller S, Molinolo AA, Fetsch P, Filie AC, O'Connell MP, Banister CE, Howard JD, Buckhaults P, Weeraratna AT, Brody LC, Rosenberg SA, Samuels Y.

Nat Genet. 2009 May;41(5):518-20. doi: 10.1038/ng.340. Epub 2009 Mar 29.

45.

PKC and PKA phosphorylation affect the subcellular localization of claudin-1 in melanoma cells.

French AD, Fiori JL, Camilli TC, Leotlela PD, O'Connell MP, Frank BP, Subaran S, Indig FE, Taub DD, Weeraratna AT.

Int J Med Sci. 2009;6(2):93-101. Epub 2009 Mar 12.

46.

Sperm-derived SPANX-B is a clinically relevant tumor antigen that is expressed in human tumors and readily recognized by human CD4+ and CD8+ T cells.

Almanzar G, Olkhanud PB, Bodogai M, Dell'agnola C, Baatar D, Hewitt SM, Ghimenton C, Tummala MK, Weeraratna AT, Hoek KS, Kouprina N, Larionov V, Biragyn A.

Clin Cancer Res. 2009 Mar 15;15(6):1954-63. doi: 10.1158/1078-0432.CCR-08-1290. Epub 2009 Mar 10.

47.

Transcriptome analysis of murine thymocytes reveals age-associated changes in thymic gene expression.

Lustig A, Carter A, Bertak D, Enika D, Vandanmagsar B, Wood W, Becker KG, Weeraratna AT, Taub DD.

Int J Med Sci. 2009;6(1):51-64. Epub 2009 Feb 9.

48.

Filamin A modulates kinase activation and intracellular trafficking of epidermal growth factor receptors in human melanoma cells.

Fiori JL, Zhu TN, O'Connell MP, Hoek KS, Indig FE, Frank BP, Morris C, Kole S, Hasskamp J, Elias G, Weeraratna AT, Bernier M.

Endocrinology. 2009 Jun;150(6):2551-60. doi: 10.1210/en.2008-1344. Epub 2009 Feb 12.

49.

Wnt5A activates the calpain-mediated cleavage of filamin A.

O'Connell MP, Fiori JL, Baugher KM, Indig FE, French AD, Camilli TC, Frank BP, Earley R, Hoek KS, Hasskamp JH, Elias EG, Taub DD, Bernier M, Weeraratna AT.

J Invest Dermatol. 2009 Jul;129(7):1782-9. doi: 10.1038/jid.2008.433. Epub 2009 Jan 29.

50.

Assaying Wnt5A-mediated invasion in melanoma cells.

O'Connell MP, French AD, Leotlela PD, Weeraratna AT.

Methods Mol Biol. 2008;468:243-53. doi: 10.1007/978-1-59745-249-6_19.

Supplemental Content

Loading ...
Support Center